Xencor (XNCR)
(Delayed Data from NSDQ)
$21.74 USD
-0.17 (-0.78%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $21.74 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Xencor, Inc. [XNCR]
Reports for Purchase
Showing records 141 - 160 ( 218 total )
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Xencor, Inc.
Industry: Medical - Drugs
''5871 Succeeds in Ph 2 IgG4-RD, Sets up Start of First Internal Ph 3 Next Year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Biotechnology - SITC Meeting Preview for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Q2; Steady Clinical Progress Confirms Long-Term Thesis
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of Aug 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Update Shows Response Rate Remains High with XmAb5871 in IgG4-RD
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Favorable Response Rates with MOR208 Combo Therapy in r/r DLBCL Reported at ASCO
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
ASCO 2017 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
1Q, Key Data Readouts Next Half, Trimming PT to $29 (from $33) as ''7195 Likely to be Partnered Off Prior to Ph 2, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of April 17
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
Company: Xencor, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences Upcoming Events for the Week of April 10.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
4Q/FY16, Well Capitalized with Key Catalysts up Ahead this Year, Reiterate OP and Raising PT to $33
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Xencor, Inc.
Industry: Medical - Drugs
ASH 2016: Additional Abstracts and Sessions of Interest
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D